Resources

In a rapidly evolving healthcare landscape, artificial intelligence (AI) is emerging as a transformative force in drug development and clinical research. With the average cost of bringing a new drug to market soaring to $1.3 billion and a low probability of success, the stakes for innovation have never been higher.

HES is a group of rare disorders characterized by persistent hypereosinophilia in blood and/or tissues, causing organ damage/dysfunction; real-world treatment patterns of patients with I-HES or L-HES remain unknown.

Adverse Drug Events (ADEs) or Adverse Drug Reactions (ADRs) continue to be a concern both in new and existing medicines. According to Medication Safety Data published by the U.S. Centers for Disease Control and Prevention (CDC), ADEs cause more than 1.5 million emergency department (ED) visits each year and nearly 500,000 patients are hospitalized after these ED visits

In the dynamic world of healthcare, real-world data (RWD) and the real-world evidence (RWE) derived from it stand as a crucial pillar for informed insights and actions.

Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare solutions.   

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

In an era defined by rapid advancements in technology and science, healthcare research and clinical trials are undergoing a transformative shift. At the heart of this revolution is data—vast, diverse, and ever-growing—and the collaborative efforts of stakeholders across the healthcare ecosystem.

The use of real-world evidence (RWE) in regulatory decision-making and health technology assessments (HTA) is gaining traction, particularly in the evolving landscape of oncology pharmacotherapeutics in Europe where navigating the drug approval and market access processes is becoming more complex.

In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation

Cancer clinical trials have long been the cornerstone of advancements in oncology, guiding the development of new therapies and improving patient outcomes.

Artificial intelligence (AI) has the potential to revolutionize drug development by leveraging real-world data (RWD) from electronic health records, claims data, patient registries, and wearable devices.